CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Botulinum Toxin Type A - Azzalure +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01014871
NCT01014871Phase 2Completed
CompareCT.gov

Intra-individual Comparison of the Efficacy of Two Botulinum Toxins Type A on Moderate to Severe Forehead Wrinkles After One Injection

Galderma R&D·interventional·Posted Nov 17, 2009·Updated Feb 18, 2021

In Brief

A Phase 2 clinical trial evaluating Botulinum Toxin Type A - Azzalure and Botulinum Toxin Type A - Vistabel for Wrinkles. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Single-centre, controlled, randomized, evaluator-blinded, bilateral (split-face) comparison study in subjects with moderate to severe forehead wrinkles. One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWrinkles
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2009
Enrollment StartJul 1, 2009
Primary CompletionApr 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.6 years ago

Interventions

Botulinum Toxin Type A - Azzaluredrug

One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.

Botulinum Toxin Type A - Vistabeldrug

One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.